Axitinib
- Generic Name
- Axitinib
- Brand Names
- Inlyta, Axitinib Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C22H18N4OS
- CAS Number
- 319460-85-0
- Unique Ingredient Identifier
- C9LVQ0YUXG
- Background
Axitinib is a second generation tyrosine kinase inhibitor that works by selectively inhibiting vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3). Through this mechanism of action, axitinib blocks angiogenesis, tumour growth and metastases. It is reported to exhibit potency that is 50-450 times higher than that of the first generation V...
- Indication
Used in kidney cell cancer and investigated for use/treatment in pancreatic and thyroid cancer.
- Associated Conditions
- Advanced Renal Cell Carcinoma, Advanced Thyroid cancer
- Associated Therapies
- First Line Chemotherapy
A Study to Compare Treatments for a Type of Kidney Cancer Called TFE/Translocation Renal Cell Carcinoma (tRCC)
- Conditions
- Interventions
- First Posted Date
- 2018-07-23
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 15
- Registration Number
- NCT03595124
- Locations
- ๐บ๐ธ
Nebraska Medicine Heartland Hematology Oncology, Kearney, Nebraska, United States
๐บ๐ธCTCA at Western Regional Medical Center, Goodyear, Arizona, United States
๐บ๐ธChildren's Hospital of Alabama, Birmingham, Alabama, United States
Safety, Tolerability and Efficacy of Vaginal Suppositories for Treatment of the Endometriosis
- Conditions
- Interventions
- First Posted Date
- 2018-03-29
- Last Posted Date
- 2021-10-29
- Lead Sponsor
- BioGene Pharmaceutical Ltd.
- Registration Number
- NCT03481842
- Locations
- ๐จ๐ญ
BioGene Pharmaceutical Ltd., Basel, ะรขlะต, Switzerland
Survival Prolongation by Rationale Innovative Genomics
- Conditions
- Interventions
- First Posted Date
- 2017-12-29
- Last Posted Date
- 2023-12-18
- Lead Sponsor
- Worldwide Innovative Network Association
- Target Recruit Count
- 15
- Registration Number
- NCT03386929
- Locations
- ๐บ๐ธ
Avera Cancer Center, Sioux Falls, South Dakota, United States
๐ฑ๐บCentre Hospitalier Luxembourg, Luxembourg, Luxembourg
๐ฎ๐ฑChaim Sheba Medical Center, Ramat Gan, Israel
Neoadjuvant AXITINIB and AVELUMAB for Patients With Localized Clear-cell RCC
- First Posted Date
- 2017-11-14
- Last Posted Date
- 2018-05-21
- Lead Sponsor
- The Netherlands Cancer Institute
- Target Recruit Count
- 40
- Registration Number
- NCT03341845
- Locations
- ๐ณ๐ฑ
Antoni van Leeuwenhoek, Amsterdam, Netherlands
Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)
- Conditions
- Interventions
- First Posted Date
- 2017-09-29
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- Canadian Cancer Trials Group
- Target Recruit Count
- 720
- Registration Number
- NCT03297606
- Locations
- ๐จ๐ฆ
Verspeeten Family Cancer Centre, London, Ontario, Canada
๐จ๐ฆCross Cancer Institute, Edmonton, Alberta, Canada
๐จ๐ฆBCCA - Kelowna, Kelowna, British Columbia, Canada
Clinical Trial on the Combination of Avelumab and Axitinib for the Treatment of Patients With Recurrent Glioblastoma
- Conditions
- Interventions
- First Posted Date
- 2017-09-25
- Last Posted Date
- 2019-01-23
- Lead Sponsor
- Universitair Ziekenhuis Brussel
- Target Recruit Count
- 52
- Registration Number
- NCT03291314
- Locations
- ๐ง๐ช
UZ Brussel, Brussel, Belgium
Study of Nivolumab and Axitinib in Patients With Advanced Renal Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2017-06-01
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Fox Chase Cancer Center
- Target Recruit Count
- 98
- Registration Number
- NCT03172754
- Locations
- ๐บ๐ธ
Johns Hopkins, Baltimore, Maryland, United States
๐บ๐ธUS Oncology and Hematology, Albany, New York, United States
๐บ๐ธFox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Axitinib With or Without Anti-OX40 Antibody PF-04518600 in Treating Patients With Metastatic Kidney Cancer
- First Posted Date
- 2017-03-28
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- University of Southern California
- Target Recruit Count
- 62
- Registration Number
- NCT03092856
- Locations
- ๐บ๐ธ
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
๐บ๐ธUniversity of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States
๐บ๐ธCleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
The Drug Rediscovery Protocol (DRUP Trial)
- Conditions
- Interventions
- Drug: PanitumumabDrug: OlaparibDrug: CrizotinibDrug: ErlotinibDrug: AlectinibDrug: Ipilimumab and nivolumabDrug: SunitinibDrug: Trastuzumab and Pertuzumab (combination treatment)Drug: Vemurafenib and Cobimetinib (combination treatment)Drug: NivolumabDrug: Dabrafenib and trametinibDrug: SelpercatinibDrug: TepotinibDrug: AbemaciclibDrug: ErdafitinibDrug: Atezolizumab and BevacizumabDrug: DacomitinibDrug: DabrafenibDrug: NilotinibDrug: TrametinibDrug: VismodegibDrug: RegorafenibDrug: AfatinibDrug: RibociclibDrug: LenvatinibDrug: PembrolizumabDrug: DurvalumabDrug: RucaparibDrug: AxitinibDrug: PalbociclibDrug: CabozantinibDrug: EntrectinibDrug: TalazoparibDrug: LorlatinibDrug: AlpelisibDrug: NiraparibDrug: Pemigatinib
- First Posted Date
- 2016-10-05
- Last Posted Date
- 2024-01-24
- Lead Sponsor
- The Netherlands Cancer Institute
- Target Recruit Count
- 1550
- Registration Number
- NCT02925234
- Locations
- ๐ณ๐ฑ
Meander medisch centrum, Amersfoort, Netherlands
๐ณ๐ฑNetherlands Cancer Institute, Amsterdam, Netherlands
๐ณ๐ฑAmsterdam UMC, locatie AMC, Amsterdam, Netherlands
Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib and Avelumab/Axitinib in Patients With MSS Recurrent or Persistent Endometrial Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-09-23
- Last Posted Date
- 2024-07-05
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 106
- Registration Number
- NCT02912572
- Locations
- ๐บ๐ธ
University of Chicago, Chicago, Illinois, United States
๐บ๐ธBeth Israel Deaconess Medical Center, Boston, Massachusetts, United States
๐บ๐ธDana Farber Cancer Institute, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.